Investors

Overview

Corporate Profile

Gamida Cell is a clinical-stage biopharmaceutical company committed to developing novel cell therapies with the potential to cure difficult-to-treat cancers and rare, serious hematologic diseases. We are leveraging our proprietary nicotinamide-based cell expansion technology, or NAM technology, to develop product candidates designed to address the limitations of cell therapies.

Copyright West LLC. Minimum 15 minutes delayed.

Latest News

View All
Sep 11, 2019

Gamida Cell and the CIBMTR Announce Collaboration to Advance Research for Life-Saving Cellular Therapy

Read More
Aug 06, 2019

Gamida Cell Reports Second Quarter 2019 Financial Results and Provides Company Update

Read More
Jul 23, 2019

Gamida Cell Announces the Date of Its Second Quarter 2019 Financial Results and Webcast

Read More
Jul 08, 2019

Gamida Cell Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares

Read More
Jun 26, 2019

Gamida Cell Announces Pricing of $35 Million Public Offering of Ordinary Shares

Read More
Jun 24, 2019

Gamida Cell Announces Launch of Proposed Public Offering of Ordinary Shares

Read More
Jun 19, 2019

Gamida Cell and Lonza Establish Commercial Manufacturing Agreement for Omidubicel

Read More
Jun 05, 2019

Gamida Cell Bolsters Management Team with Appointment of Tracey Lodie, Ph.D., as Chief Scientific Officer

Read More
May 31, 2019

Gamida Cell Announces Data for Omidubicel Presented at the International Society for Cellular and Gene Therapy 2019 Annual Meeting

Read More
May 29, 2019

Gamida Cell to Hold Annual Meeting of Stockholders

Read More
May 09, 2019

Gamida Cell to Participate in Two Upcoming Healthcare Conferences in New York City

Read More
May 07, 2019

Gamida Cell Reports First Quarter 2019 Financial Results and Provides Company Update

Read More
Apr 30, 2019

Gamida Cell Announces the Date of Its First Quarter 2019 Financial Results and Webcast

Read More
Apr 22, 2019

Gamida Cell to Present at the Solebury Trout Class of 2018 Biotech IPOs Investor Day

Read More
Apr 05, 2019

Gamida Cell to Present at the 18th Annual Needham Healthcare Conference

Read More
Mar 21, 2019

Gamida Cell Nominates Two Healthcare Industry Veterans to Its Board of Directors

Read More
Feb 25, 2019

Gamida Cell Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update

Read More
Feb 23, 2019

Gamida Cell Announces Immune Reconstitution Data from Completed Phase 1/2 Clinical Study of NiCord® Presented at 2019 TCT Annual Meeting

Read More
Feb 21, 2019

Gamida Cell Presents New Data from Ongoing Phase 1 Study of NAM-NK and Initial Data from Phase 1/2 Study of NiCord® in Severe Aplastic Anemia at 2019 TCT Annual Meeting

Read More
Feb 19, 2019

Gamida Cell Announces Agreement with Editas Medicine to Evaluate Use of CRISPR Genome Editing Technology in NAM-NK Cells

Read More
Upcoming Events
More events are coming soon.
Recent Events

Investor & Media Contact

Jaren Irene Madden
Vice President of Investor Relations and Corporate Communications
Gamida Cell Ltd.
IRPR@gamida-cell.com